GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Cyclically Adjusted PB Ratio

Galectin Therapeutics (Galectin Therapeutics) Cyclically Adjusted PB Ratio : 12.54 (As of May. 01, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Galectin Therapeutics's current share price is $3.51. Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.28. Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is 12.54.

The historical rank and industry rank for Galectin Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

GALT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 15.06
Current: 12.55

During the past years, Galectin Therapeutics's highest Cyclically Adjusted PB Ratio was 15.06. The lowest was 0.00. And the median was 0.00.

GALT's Cyclically Adjusted PB Ratio is ranked worse than
93.01% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs GALT: 12.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galectin Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $-1.010. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.28 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galectin Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galectin Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Cyclically Adjusted PB Ratio Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.47 6.57 5.31 3.23 5.94

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 6.17 4.38 6.23 5.94

Competitive Comparison of Galectin Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.



Galectin Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.51/0.28
=12.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.01/129.4194*129.4194
=-1.010

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.264 99.695 1.641
201406 1.142 100.560 1.470
201409 1.024 100.428 1.320
201412 0.926 99.070 1.210
201503 0.897 99.621 1.165
201506 0.728 100.684 0.936
201509 0.513 100.392 0.661
201512 0.607 99.792 0.787
201603 0.411 100.470 0.529
201606 0.237 101.688 0.302
201609 0.125 101.861 0.159
201612 0.093 101.863 0.118
201703 0.019 102.862 0.024
201706 -0.090 103.349 -0.113
201709 -0.177 104.136 -0.220
201712 -0.217 104.011 -0.270
201803 -0.168 105.290 -0.207
201806 0.020 106.317 0.024
201809 0.000 106.507 0.000
201812 -0.050 105.998 -0.061
201903 0.100 107.251 0.121
201906 0.872 108.070 1.044
201909 0.833 108.329 0.995
201912 0.762 108.420 0.910
202003 0.710 108.902 0.844
202006 0.609 108.767 0.725
202009 0.515 109.815 0.607
202012 0.384 109.897 0.452
202103 0.280 111.754 0.324
202106 0.251 114.631 0.283
202109 0.118 115.734 0.132
202112 0.006 117.630 0.007
202203 -0.142 121.301 -0.152
202206 -0.294 125.017 -0.304
202209 -0.413 125.227 -0.427
202212 -0.579 125.222 -0.598
202303 -0.753 127.348 -0.765
202306 -0.896 128.729 -0.901
202309 -0.859 129.860 -0.856
202312 -1.010 129.419 -1.010

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galectin Therapeutics  (NAS:GALT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galectin Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (Galectin Therapeutics) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025

Galectin Therapeutics (Galectin Therapeutics) Headlines

From GuruFocus